TriangleNCT00859937 · OUTCOME
Response Rate
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 2 months
What was measured
Response rate is percentage of the best overall response which recoded from the start of the treatment until diseases progression/recurrence. Response criteria are defined using the international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee: Complete Response, Disappearance of all target lesions; Partial Response, \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.
Analysis population: There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.
Groups in this outcome
Adenoid Cystic Carcinoma
Patients with Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Non Adenoid Cystic Carcinoma
Patients with non Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Adenoid Cystic Carcinoma | 40 |
| Non Adenoid Cystic Carcinoma | 14 |
Reported measurements
Complete response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adenoid Cystic Carcinoma | 0 | Not reported | Not reported | Not reported | Not reported |
| Non Adenoid Cystic Carcinoma | 0 | Not reported | Not reported | Not reported | Not reported |
Partial response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adenoid Cystic Carcinoma | 1 | Not reported | Not reported | Not reported | Not reported |
| Non Adenoid Cystic Carcinoma | 0 | Not reported | Not reported | Not reported | Not reported |
Stable disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adenoid Cystic Carcinoma | 20 | Not reported | Not reported | Not reported | Not reported |
| Non Adenoid Cystic Carcinoma | 7 | Not reported | Not reported | Not reported | Not reported |
Progressive disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adenoid Cystic Carcinoma | 12 | Not reported | Not reported | Not reported | Not reported |
| Non Adenoid Cystic Carcinoma | 4 | Not reported | Not reported | Not reported | Not reported |
Other
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adenoid Cystic Carcinoma | 7 | Not reported | Not reported | Not reported | Not reported |
| Non Adenoid Cystic Carcinoma | 3 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- Complete response
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- title
- Partial response
- categories
- measurements
- group Id
- OG000
- value
- 20
- group Id
- OG001
- value
- 7
- title
- Stable disease
- categories
- measurements
- group Id
- OG000
- value
- 12
- group Id
- OG001
- value
- 4
- title
- Progressive disease
- categories
- measurements
- group Id
- OG000
- value
- 7
- group Id
- OG001
- value
- 3
- title
- Other
- denoms
- counts
- group Id
- OG000
- value
- 40
- group Id
- OG001
- value
- 14
- units
- Participants
- description
- Response rate is percentage of the best overall response which recoded from the start of the treatment until diseases progression/recurrence. Response criteria are defined using the international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee: Complete Response, Disappearance of all target lesions; Partial Response, \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.
- groups
- description
- Patients with Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Adenoid Cystic Carcinoma
- description
- Patients with non Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG001
- title
- Non Adenoid Cystic Carcinoma
- param Type
- NUMBER
- population Description
- There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.
- reporting Status
- POSTED
- time Frame
- Up to 2 months
- title
- Response Rate
- type
- PRIMARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice